Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

"This is the first time I'm really talking about it publicly… but you just get that 'aha' moment where you realize 'I wasn't put in this position to not utilize my voice and my platform for good." La ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis ... looks towards extending its use into other chronic inflammatory diseases like inflammatory ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for ...

Almost half the plaque psoriasis patients suffer from scalp involvement ... Our goal is to make a positive and meaningful ...

In a first-in-human Phase 1 clinical trial to test CAL101 in 57 participants, healthy volunteers were given single ascending doses of the therapy, while people with chronic plaque psoriasis, a chronic ...